Solanezumab is a humanized monoclonal IgG1 antibody which is directed against the mid-domain of the Aβ peptide. By sequestering Aβ, shifting equilibria between different species of Aβ, and removing small soluble species of Aβ that are directly toxic to synaptic function, it may exert benefit.
Solanezumab is a humanized monoclonal antibody that targets soluble amyloid-beta (Aβ) peptides, a class of peptides implicated in neurodegenerative processes and protein aggregation disorders. As an immunoglobulin G1 (IgG1) molecule, it is engineered to selectively bind to the central epitope of the Aβ peptide, thereby modulating the dynamics of amyloid species in extracellular environments. The compound's high specificity for soluble amyloid-beta makes it a valuable research reagent for elucidating the molecular mechanisms of amyloid processing, aggregation, and clearance. Its development has contributed significantly to advancing the understanding of protein misfolding pathologies and the role of immune-mediated targeting in altering disease-relevant pathways.
Amyloid-beta aggregation studies: Solanezumab is extensively utilized in in vitro and in vivo models to investigate the dynamics of amyloid-beta aggregation and disaggregation. By selectively binding to soluble forms of Aβ, it allows researchers to dissect the equilibrium between monomeric, oligomeric, and fibrillar states of amyloid-beta. This property is instrumental in exploring the biochemical pathways that govern amyloid plaque formation, providing insight into the molecular events that precede and accompany pathological aggregation in neurodegenerative disease models.
Mechanistic research on antibody-peptide interactions: The antibody's unique epitope specificity serves as a model system for studying the interaction between monoclonal antibodies and pathogenic peptides. Researchers employ solanezumab to analyze binding kinetics, affinity, and structural determinants of antibody-peptide recognition using techniques such as surface plasmon resonance, isothermal titration calorimetry, and X-ray crystallography. These studies inform the rational design of next-generation antibodies and peptide-targeting biologics, deepening the scientific community's understanding of antigen recognition and immune modulation.
Biomarker development and validation: In the context of biomarker research, solanezumab is applied as a reference antibody in immunoassays designed to quantify soluble amyloid-beta species in biological fluids such as cerebrospinal fluid and plasma. Its established binding profile enables the development and validation of sensitive and specific assays, facilitating the monitoring of amyloid-beta dynamics in preclinical and translational research. Such assays are critical for evaluating the efficacy of compounds targeting amyloidogenic pathways and for identifying early biochemical changes associated with neurodegeneration.
Preclinical evaluation of immunotherapeutic strategies: The antibody is routinely incorporated into preclinical studies aimed at evaluating the impact of passive immunization on amyloid-beta clearance and downstream neurobiological effects. By administering solanezumab in animal models, researchers can assess changes in amyloid burden, synaptic integrity, and neuroinflammatory responses. These investigations provide essential data on the mechanistic consequences of antibody-mediated Aβ targeting, supporting the refinement of immunotherapeutic approaches for protein aggregation disorders.
Tool for studying peripheral sink hypothesis: Solanezumab's ability to sequester soluble amyloid-beta in the periphery has made it a valuable tool for testing the peripheral sink hypothesis, which posits that peripheral clearance of Aβ can reduce central nervous system amyloid levels. Experimental protocols employing the antibody in animal models and ex vivo systems help clarify the kinetics of Aβ transport and the interplay between central and peripheral pools. These studies contribute to a more nuanced understanding of amyloid homeostasis and inform the development of strategies to manipulate peptide distribution across biological compartments.
1. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes
2. Emu oil in combination with other active ingredients for treating skin imperfections
5. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More